By Fineline Cube 
France-based BioMérieux is set to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company leveraging genomic sequencing and machine learning to combat the growing threat of antibiotic-resistant infections.
Integration Benefits
While Day Zero Diagnostics’ solutions are still in development, their integration will strengthen bioMérieux’s R&D pipeline. This move aims to provide rapid and accurate diagnostic tools to address unmet needs in infectious disease testing, particularly for life-threatening conditions like sepsis.
Breakthrough Technology
Day Zero Diagnostics has developed breakthrough technology that combines direct – from – blood sample preparation, sequencing, and advanced identification/antimicrobial susceptibility testing (ID/AST) analysis. The company’s sequencing-based rapid diagnostic approach can identify bacterial pathogens and their antibiotic resistance profiles within hours, compared to the 2 – 5 days required by conventional methods.
Acquired Assets
The acquired assets include next-generation sequencing (NGS) workflows, chemistry reagents and kits, and bioinformatics pipelines and software.-Fineline Info & Tech